Koselugo 10mg Capsule

About

Selumetinib, the active ingredient in Koselugo, is an oral mitogen-activated protein kinase (MEK) inhibitor indicated for the treatment of pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PNs). It works by targeting the MEK pathway, which is often overactive in NF1-related tumors, thereby inhibiting cell proliferation and tumor growth. This targeted therapy represents a significant advancement in managing the complex manifestations of NF1, particularly for patients with challenging PNs that cause significant morbidity.

The drug's mechanism involves blocking MEK1 and MEK2, key enzymes in the RAS/MAPK signaling pathway. Dysregulation of this pathway is central to the pathogenesis of NF1. By inhibiting MEK, selumetinib can reduce tumor volume, alleviate pain, and improve functional outcomes in affected children, offering a non-surgical option for managing these often debilitating tumors.

Uses

• Treatment of symptomatic, inoperable plexiform neurofibromas in NF1.
• Management of tumor growth associated with neurofibromatosis type 1.
• Reduction of pain and improvement of functional outcomes in pediatric NF1 patients.
• Targeted therapy for specific genetic mutations in the RAS/MAPK pathway.

Directions For Use

Take this medicine orally, usually twice daily, with or without food. Follow your doctor's instructions regarding dosage and duration.

Benefits

• Reduces tumor volume in plexiform neurofibromas.
• Alleviates pain associated with NF1-related tumors.
• Improves quality of life for pediatric NF1 patients.
• Offers a non-surgical treatment option for inoperable tumors.
• Targets a specific pathway involved in NF1 pathogenesis.
• Demonstrated efficacy in clinical trials for its approved indication.

Side Effects

• Vomiting
• Diarrhea
• Nausea
• Skin rash
• Fatigue
• Dry skin
• Paronychia (nail inflammation)
• Stomatitis (mouth sores)
• Pruritus (itching)
• Pyrexia (fever)
• Abdominal pain
• Musculoskeletal pain

Safety Measures

• Alcohol - Consult your doctor regarding alcohol consumption, as it may exacerbate certain side effects or interact with the medication.
• Pregnancy - Selumetinib is not recommended during pregnancy due to potential fetal harm. Effective contraception is advised for women of childbearing potential.
• Breastfeeding - It is generally advised to avoid breastfeeding during treatment with selumetinib and for a period after the last dose, due to potential excretion into breast milk.
• Liver - Use with caution in patients with hepatic impairment. Dose adjustments may be necessary, and liver function should be monitored regularly.
• Kidney - No specific dose adjustment is typically required for mild to moderate renal impairment, but caution is advised in severe cases.
• Lung - Monitor for new or worsening respiratory symptoms, as interstitial lung disease or pneumonitis can occur.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.